MedTrace Logo

Feasibility Study for the Assessment of Sleep Quality in Men With Prostate Cancer Starting ADT

NCT02919904 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2019-10-03

No results posted yet for this study

Summary

The feasibility of using the Apnea Risk Evaluating System (ARESTM) device to take longitudinal measures of sleep parameters in asymptomatic men with prostate cancer who are about to initiate androgen deprivation therapy (ADT) will be evaluated. Study participants will complete serial questionnaires relating to sleep quality, hot flashes, and quality of life.

Conditions

  • Prostatic Neoplasms
  • Sleep

Interventions

DEVICE

ARESTM

The ARESTM device is a commercial home sleep-testing device that can record the following parameters (for up to 7 continuous hours) when participants are asleep: * NREM and REM sleep frequency and duration * Duration and number of arousal * Blood oxygen saturation and pulse rate via a silicone-embedded optical sensor * Fluctuation in nasal airflow pressure via a nasal cannula and pressure transducer * Head movement actigraphy and flux in snoring as measures of sleep/wake patterns via two accelerometers and an acoustic microphone * Apnea/hypopnea index and respiratory disturbance index

Sponsors & Collaborators

  • Vancouver Prostate Centre

    lead OTHER

Principal Investigators

  • Larry Goldenberg, MD · University British Columbia

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02919904 on ClinicalTrials.gov